Grippferon spray, 10ml

Prevention and treatment of influenza and ARVI in children and adults.

At the first signs of the disease, GrippferonЃ is used for 5 days:

- at the age of 0 to 1 year, 1 dose (500 ME) is injected into each nasal passage 5 times a day (single dose of 1000 ME, daily dose of 5000 ME);

- at the age of 1 to 3 years, 2 doses are injected into each nasal passage 3-4 times a day (single dose 2000 ME, daily dose 6000-8000 ME);

- at the age of 3 to 14 years, 2 doses are injected into each nasal passage 4-5 times a day (single dose 2000 ME, daily dose 8000-10000 ME);

- from the age of 15 and adults, 3 doses are injected into each nasal passage 5-6 times a day (a single dose of 3000 IU, a daily dose of 15000-18000 IU).

In order to prevent ARVI and influenza:

- upon contact with a patient and / or hypothermia, the drug is injected at a single age dosage 2 times a day once;

- with a seasonal increase in morbidity, the drug is injected at an age-specific dosage once in the morning with an interval of 24-48 hours.

- If necessary, prophylactic courses are repeated.

To inject the drug, remove the protective cap, insert the spray device into the nasal passage and press the spray mechanism strongly (1 dose -1 press). Before the first use, press the spray mechanism several times until a cloud of spray appears.

Dosed nasal spray in the form of a clear colorless or light yellow solution.

1 ml 1 dose

interferon alpha-2b human recombinant 10000 IU 500 IU

Excipients: disodium edetate dihydrate 0.5 mg, sodium chloride 4.1 mg, sodium hydrogen phosphate dodecahydrate 11.94 mg, potassium dihydrogen phosphate 4.54 mg, povidone 8 thousand 10 mg, macrogol 4000 100 mg, purified water to 1 ml.

• Individual intolerance to interferon preparations and the components that make up the drug;

• severe forms of allergic diseases.

Pharmacodynamics

The drug has immunomodulatory, anti-inflammatory and antiviral effects.

Pharmokinetics

With intranasal administration, the concentration of the active substance reached in the blood is significantly lower than the detection limit (the limit of determination of interferon alpha-2b -1-2 IU / ml) and has no clinical significance.

Side effects

Not marked.

Special conditions

The drug does not affect the ability to drive vehicles and mechanisms.

Drug interactions

The use of intranasal vasoconstrictor drugs in conjunction with GrippferonЃ is not recommended, as this contributes to additional drying of the nasal mucosa.